Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab Combined With Gemcitabine and Cisplatin in Advanced Intrahepatic Cholangiocarcinoma
NCT05781958Phase 2Unknown
- Sponsor
- Shenfeng Biological
- Start
- Nov 2022
- Primary completion
- Dec 2023
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in intrahepatic cholangiocarcinoma (ICC), sponsored by Shenfeng Biological. Primary endpoint: Objective Response Rate. Status: unknown.
02
Drugs
cadonilimab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT05781958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05781958.